In one paragraphArticle in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
28 authors.
Mateus Rozalem-AranhaSant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
José Allende ParraSant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Susana FernándezBarcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain.
Alexandre BejaninSant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Funding
DS-ARC: A Remote Digital Cognitive Assessment for Down Syndrome-Associated Alzheimer's DiseaseR01AG081394 · NIA · WASHINGTON UNIVERSITY · PI Jason J Hassenstab · 2023 to 2026
$6.0MThe Role of Inflammation and NGF Dysfunction in the Evolution of Alzheimer Disease Pathology in Down Syndrome-RevisionRF1AG056850 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI BUSCIGLIO, JORGE A, CUELLO, A CLAUDIO · 2018 to 2020
$5.9MClinical trials to prevent Alzheimer's Disease in Down SyndromeR61AG066543 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RAFII, MICHAEL S · 2019 to 2020
$5.6MTau pathology in Down syndrome and Alzheimer'sRF1AG061566 · NIA · UNIVERSITY OF DENVER (COLORADO SEMINARY) · PI GRANHOLM-BENTLEY, ANN-CHARLOTTE ESTHER, MARGITTAI, MARTIN · 2019 to 2019
$3.4MBilingual Factors Associated with Cognitive Reserve and Linguistic Resilience in Hispanics with Primary Progressive AphasiaR01AG080470 · NIA · UNIVERSITY OF TEXAS AT AUSTIN · PI Stephanie M Grasso · 2023 to 2026
$2.8MBiological Correlates of Alzheimer in Down Syndrome.R21AG056974 · NIA · UNIVERSITY OF DENVER (COLORADO SEMINARY) · PI GRANHOLM-BENTLEY, ANN-CHARLOTTE ESTHER · 2017 to 2018
$414kAjuntament de Barcelona, in collaboration with Fundació La Caixa 23S06157-001Alzheimer's Association AACSF-21-850193Alzheimer's Association AACSF-22-972945Alzheimer's Association AACSF-25-1486364Alzheimer's Association AARF-22-924456Alzheimer's Association AARFD-21-852492Alzheimer's Association AARG-22-923680Alzheimer's Association AARG-22-973966Alzheimer's Association AARG-22-974373Centro de Investigación Biomédica en Red sobre Enfermedades NeurodegenerativasDepartment de Salut de la Generalitat de Catalunya SLT006/17/00119Department of Health Generalitat de Catalunya PERIS program SLT006/17/125Department of Research and Universities from the Generalitat de Catalunya 2021SGR00979Fondation Jérôme Lejeune #1801Cycle2020Fondation Jérôme Lejeune #1913cycle2019BFondation Jérôme Lejeune 2326-GRT-2024AFondation Jérôme Lejeune #2425cycle2024BFondation Jérôme Lejeune #51PDC-2023-51Fundación LuzónFundación Tatiana Pérez de Guzmán el Bueno IIBSP-DOW-2020-151FUNDELAGlobal Brain Health Institute GBHI_ALZ-18-543740Global Brain Health Institute GBHI_ALZ-23-971107Global Brain Health Institute GBHIALZUK-21-72097Horizon 2020 - Research and Innovation Framework Programme from the European Union H2020-SC1-BHC-2018-2020Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF CD23/00235Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF CM22/00052Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF CM22/00243Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF CM23/00291Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF CP20/00038Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF CP24/00112Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF DTS22/00111Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF ICI23/00032Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF INT19/00016Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF INT21/00073Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF INT23/00048Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF JR18-00018Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF JR20/0018Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF PI18/00335Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF PI18/00435Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF PI19/00882Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF PI20/00836Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF PI20/01473Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF PI21/00063Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF PI21/00791Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF PI21/01395Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF PI22/00307Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF PI22/00611Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF PI22/00758Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF PI23/01786Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF PI24/00598Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF PI24/00968Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. ERDF PI24/01087NIA NIH HHS R01 AG080470NIA NIH HHS R01 AG081394NIA NIH HHS R21 AG056974NIA NIH HHS R61 AG066543NIA NIH HHS RF1 AG056850NIA NIH HHS RF1 AG061566NIH HHS 1R01AG056850-01A1NIH HHS 1R01AG081394-01NIH HHS 1R61AG066543-01NIH HHS R01AG061566NIH HHS R01AG080470NIH HHS R21AG056974
6 · The paper itselfAbstract
introductionThis study investigates the evolution with disease progression and pathological correlates of peak width of skeletonized mean diffusivity (PSMD), a sensitive diffusion magnetic resonance imaging (MRI) marker of microvascular white matter (WM) injury, in sporadic Alzheimer's disease (sAD) and Down syndrome (DS)-associated AD (DSAD).
methodThis cross-sectional study included 150 euploid controls, 118 subjects with sAD, and 228 DS adults (34.65% with symptomatic AD). PSMD was derived from 3T-MRI diffusion tensor imaging. Associations with sociodemographic, clinical stage, cerebrospinal fluid (CSF), and small vessel disease markers were examined.
resultsPSMD correlated with age in all groups, showing a stronger association in DS, with alterations apparent 15 years before the population's dementia age at onset. In euploid and DS, higher PSMD correlated with AD severity, CSF-neurofilament light chain (NfL), microbleeds, and WM hyperintensities (WMH). PSMD abnormalities were more frequent than WMH, especially in DS. DISCUSSION: PSMD is a sensitive early biomarker of WM injury across sAD and DSAD, preceding symptom onset and capturing multifactorial disease processes.
Indexed as
Alzheimer DiseaseDown SyndromeWhite MatterAgedBrainCross-Sectional StudiesDiffusion Magnetic Resonance ImagingDiffusion Tensor ImagingDisease ProgressionFemaleHumansMaleMiddle AgedAlzheimer's diseasediffusion‐weighted imagingDown syndromemagnetic resonance imagingsmall vessel diseasewhite matter integrity
Identifiers
PMID42212383
PMCPMC13240567
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390